| Literature DB >> 32252630 |
Mitsuhito Koizumi1, Teru Kumagi2, Taira Kuroda1, Yoshiki Imamura1, Kozue Kanemitsu1, Kohei Ogawa3, Yasutsugu Takada3, Yoichi Hiasa1.
Abstract
BACKGROUND: Endoscopic balloon dilation and/or plastic stent placement has been a standard method for treating biliary strictures complicated post living donor liver transplantation (LDLT). The strictures may be refractory to endoscopic treatment and require long-term stent placement. However, consensus on the optimal period of the stent indwelling and usefulness of the inside stent does not exist.Entities:
Keywords: Biliary stricture; Endoscopic biliary drainage; Living donor liver transplantation
Mesh:
Year: 2020 PMID: 32252630 PMCID: PMC7137274 DOI: 10.1186/s12876-020-01226-x
Source DB: PubMed Journal: BMC Gastroenterol ISSN: 1471-230X Impact factor: 3.067
Fig. 1Procedure of endoscopic treatment for biliary stricture. a Cholangiogram shows a biliary stricture. b Placement of an inside stent across the biliary stricture above the sphincter of Oddi. c Cholangiogram shows the resolution of the stricture after exchanging the inside stent. d Whole view of an inside stent. e Duodenal papilla with inside stent placed
Outcomes of patients treated for biliary strictures after LDLT (N = 16)
| Patienta | Indications | Graft | Stricture morphology | Tip shape of the distal duct | ERCP | Endoscopic | Number of strictures | Inside Stent | Outside Stent (times) | Stent indwelling period (months) | Follow Up period (months) | Present status |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 30–39/sex 1 | Fulminant liver failure | Left | Non-visualization | Round | 1 | No | 1 | 0 | 0 | 0 | 108 | Choledochojejunostomy |
| 30–39/sex 2 | Fulminant liver failure | Left | Wide | Tapered | 14 | Yes | 1 | 11 | 1 | 105 | 105 | Inside stent |
| 50–59/sex 2 | LC-PBC | Left | Separate | Round | 8 | Yes | 1 | 8 | 0 | 85 | 85 | Inside stent |
| 60–69/sex 2 | LC-HBV | Left | Narrow | Tapered | 7 | Yes | 1 | 7 | 0 | 42 | 56 | Stricture resolution |
| 50–59/sex 1 | LC-HCV | Left | Narrow | Tapered | 5 | Yes | 1 | 3 | 0 | 19 | 35 | Stricture resolution |
| 60–69/sex 1 | LC-HCV | Left | Narrow | Tapered | 5 | Yes | 1 | 3 | 1 | 23 | 23 | Inside stent |
| 60–69/sex 2 | LC-PBC | Left | Narrow | Round | 3 | Yes | 1 | 3 | 0 | 16 | 16 | Inside stent |
| 50–59/sex 1 | LC-HBV | Right | Narrow | Tapered | 7 | Yes | 1 | 5 | 2 | 58 | 127 | Stricture resolution |
| 40–49/sex 1 | LC-HBV | Right | Non-visualization | Round | 1 | No | 2 | 0 | 0 | 0 | 124 | Choledochojejunostomy |
| 50–59/sex 1 | LC-HCV | Right | Narrow | Tapered | 8 | Yes | 2 | 5 | 2 | 17 | 93 | Stricture resolution |
| 40–49/sex 1 | LC-NASH | Right | Separate | Round | 6 | Yes | 2 | 6 | 0 | 84 | 84 | Inside stent |
| 60–69/sex 1 | LC-alcohol | Right | Separate | Tapered | 5 | Yes | 2 | 3 | 1 | 70 | 78 | Stricture resolution |
| 50–59/sex 1 | LC-alcohol | Right | Separate | Tapered | 6 | Yes | 1 | 6 | 0 | 61 | 61 | Inside stent |
| 60–69/sex 2 | LC-HCV | Right | Separate | Tapered | 4 | Yes | 1 | 4 | 0 | 19 | 52 | Stricture resolution |
| 50–59/sex 2 | LC-PBC | Right | Narrow | Tapered | 6 | Yes | 2 | 3 | 3 | 27 | 45 | Stricture resolution |
| 60–69/sex 1 | LC-HCV | Posterior | Separate | Round | 12 | Yes | 1 | 12 | 0 | 87 | 87 | Inside stent |
LDLT Living donor liver transplantation, LC-PBC Liver cirrhosis secondary to primary biliary cholangitis, HBV Hepatitis B virus, HCV Hepatitis C virus, NASH Non-alcoholic steatohepatitis
a Age and sex of the patients are not specified to anonymize the data
Fig. 2Clinical outcome of 16 patients who received stent placement against biliary strictures after LDLT
Fig. 3a Incidence of stent migration. b Incidence of stent occlusion. c Patent duration of bile duct after stent placement
Comparison of inside stent and outside stent for biliary strictures after LDLT
| Inside stent | Outside stent | ||
|---|---|---|---|
| Symptom prior to the scheduled session | 17 (22%) | 3 (30%) | 0.575 |
| Fever | 13 (16%) | 3 (30%) | 0.313 |
| Jaundice | 11 (14%) | 0 (0%) | 0.201 |
| Early complications | 9 (12%) | 1 (10%) | 0.873 |
| Pancreatitis | 3 (4%) | 1 (10%) | 0.386 |
| Cholangitis | 6 (8%) | 0 (0%) | 0.360 |
| Stone formation | 14 (18%) | 3 (30%) | 0.400 |
LDLT Living donor liver transplantation